In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...

The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...

Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...

AbbVie is also developing oncology therapies beyond ADC. A key candidate in the company’s pipeline is etentamig/ABBV-383, a ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant  given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

A tumor-informed ctDNA assay identified MRD in TNBC patients, indicating a 30-fold higher risk of distant recurrence for MRD-positive individuals. The NSABP B-59/GBG 96-GeparDouze trial involved 1550 ...